Celgene PT Lowered to $126.00 (CELG)
Analysts at Nomura decreased their target price on shares of Celgene (NASDAQ:CELG) from $252.00 to $126.00 in a research report issued to clients and investors on Monday. Nomura’s price target would suggest a potential upside of 45.16% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at JMP Securities cut their price target on shares of Celgene from $205.00 to $102.00 in a research note on Friday. They now have a “market outperform” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Celgene in a research note on Thursday. They now have a $182.00 price target on the stock. Finally, analysts at Credit Suisse reiterated an “outperform” rating on shares of Celgene in a research note on Thursday, June 19th. They now have a $112.50 price target on the stock, up previously from $105.00. One investment analyst has rated the stock with a sell rating, three have given a hold rating and fourteen have assigned a buy rating to the company. Celgene currently has an average rating of “Buy” and a consensus price target of $99.19.
Shares of Celgene (NASDAQ:CELG) opened at 86.80 on Monday. Celgene has a one year low of $59.075 and a one year high of $87.37. The stock has a 50-day moving average of $79.0 and a 200-day moving average of $78.14. The company has a market cap of $69.512 billion and a P/E ratio of 55.14.
Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, April 24th. The company reported $1.67 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.65 by $0.02. The company had revenue of $1.71 billion for the quarter, compared to the consensus estimate of $1.77 billion. During the same quarter in the prior year, the company posted $1.37 earnings per share. The company’s quarterly revenue was up 18.1% on a year-over-year basis. Analysts expect that Celgene will post $3.65 EPS for the current fiscal year.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.